Biocon is India's leading biotechnology enterprise. Established in 1978, the company today is an integrated biotechnology enterprise focused on the development of biopharmaceuticals. The company serves partners and customers in over 50 countries. Within the biotechnology space, the company ranks first in Asia in terms of revenues and market capitalisation and sixteenth globally.
The company is headed by Kiran Mazumdar-Shaw, India's second richest woman (after Sudha Gopalakrishnan, wife of Chris Gopalakrishnan, COO Infosys). She achieved this status after Biocon went for an IPO in 2004. Biocon became only the second Indian company to cross a market capitalisation of one billion U.S. $ on the first day of listing. Mazumdar-Shaw and her husband John Shaw own over 60% of the company's stock.
- Biocon is India's first biotechnology company, established in 1978
- Biocon is the country's first biotechnology company to export microbial enzymes to USA and Europe
- Biocon is the first biotechnology company to receive ISO 9001 certification in India
- Syngene, a Biocon subsidiary, is the country's first biotech custom research company in drug discovery
- Biocon is the first Indian company to be approved by US FDA for the manufacture of pplovastatin, a cholesterol-lowering molecule
- Biocon's subsidiary, Clinigene, has India's first CAP (College of American Pathologists) accredited clinical research laboratory
- Biocon is the first company to manufacture human insulin using a Pichia expression system
- Anti-Diabetic Agents
- Anti-Hypertensive Agents
- Anti-Inflammatory Agents
- Cardiovascular Agents
- Digestive Aid Enzymes
- Haemostatic Agents
- Hepatoprotective Agents
- Elliott, John (Nov. 14, 2005). "Biotech Queen". Fortune, p. 79–82.
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies